Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC inhibitor
Valproic acid is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2; Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.- Dan Zhao, .et al. , Poult Sci, 2022, Mar; 101(3): 101642 PMID: 35016046
-
CA9 inhibitor
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells. -
monoamine oxidase A inhibitor
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline. -
Carbonic anhydrase inhibitor
Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM. -
Cytochrome P450 inhibitor
Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM). -
MAO inhibitor
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor (MAOI) that is used as an antidepressive agent. -
PDE4B inhibitor
Ademetionine, also known as AdoMet; MSI-195; SAMe, S-adenosylmethionine, is a PDE4B inhibitor potentially for treatment of primary biliary cirrhosis and major depressive disorder. -
penicillin binding protein inhibitor
Cefminox Sodium, also known as Meicelin and MT-141, is a penicillin binding protein inhibitor used to treat bacterial infection. -
MAO inhibitor
Molindone HCl is a D2 dopamine receptor antagonist. It also acts as a MAO inhibitor. -
CoA reductase inhibitor
Atorvastatin, (+/-)- is a Hydroxymethylglutaryl-CoA reductase inhibitor. -
Pyruvate dehydrogenase kinase inhibitor
Sodium Dichloroacetate, also known as CPC-211; DCA; X-11S, is a Pyruvate dehydrogenase kinase inhibitor potentially for the treatment of myocardia ischemia, ischemic. Sodium dichloroacetate also exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia. -
monoamine oxidase inhibitor
Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro. -
factor Xa inhibitor
Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII). -
MAO-A inhibitor
Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAOA) inhibitor. Antidepressant. -
PDE-5 inhibitor
Mirodenafil dihydrochloride (SK3530 dihydrochloride) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. -
MAO inhibitor
Iproniazid phosphate is an irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity. -
PDE3 inhibitor
Fosphenytoin Sodium is the sodium salt form of fosphenytoin, a prodrug that is hydrolyzed to the anticonvulsant phenytoin. It is an PDE3 (phosphodiesterase 3) inhibitor. -
ATP-competitive STK19 inhibitor
ZT-12-037-01 is a potent, selective, ATP-competitive STK19 inhibitor. ZT-12-037-01 effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo. -
IDH1 inhibitor
DH1 Inhibitor 2 is a potent IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM.- Derek Dang, .et al. , Cancer Cell, 2025, Jun 9;43(6):1159-1174 PMID: 40378837
-
dual PDE7/GSK-3 inhibitor
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS). -
IDO/TDO dual inhibitor
IDO/TDO-IN-1 is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively . -
EMT inhibitor
EMT inhibitor-2 inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively. -
PDE12 inhibitor
PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC50 of 7.68. Antiviral activity. -
cNIIIB nucleotidase inhibitor
7-Methylguanosine is a novel cNIIIB nucleotidase inhibitor with IC50 value of 87.8????7.5??M. -
5-Lipoxygenase (5-LO) inhibitor
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation. -
FXIa inhibitor
BMS-962212 is a reversible, direct, and highly selective inhibitor of FXIa. -
Hsp70 inhibitor
JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages.- Mizuho Nosaka, .et al. , Sci Rep, 2023, Dec 16;13(1):22416 PMID: 38104135
- Siu Hong Dexter Wong, .et al. , Sci Adv, 2023, Jul 7;9(27):eadg9593 PMID: 37418519
- Shivani Patel, .et al. , iScience, 2022, Apr 22;25(5):104282 PMID: 35573186
-
cell motility and cell invasion inhibitor
KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life. -
5-LOX inhibitor
PF-4191834 is a novel, potent and selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain with an IC50=229 nM. displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes. -
IDH1 inhibitor
Olutasidenib is a potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 for the treatment of acute myeloid leukemia.
